Twenty-Seven Point Four Per Cent Is a Plan, Not a Forecast

A target is a share claim, and share is the one thing that can be checked

Guidance in this industry normally arrives as a revenue number, which is convenient because a revenue number cannot be audited against anything except itself. QIAGEN’s digital PCR target is more useful than that. It is small enough, and the segment it sits in is disclosed clearly enough, that the target converts into a market share — and a market share can be measured against the share the company holds today.

The arithmetic is short. QIAcuity, the company’s digital PCR platform, produced USD 89 million in 2025 against a digital PCR segment the PCR and digital PCR market report sizes at USD 600 million. That is 14.8 percent. The stated target for 2028 is USD 250 million. At 15 percent annual segment growth, USD 600 million becomes roughly USD 912 million, and USD 250 million of that is 27.4 percent.

Read that again as a sentence rather than a table. The plan is not to grow digital PCR. The plan is to roughly double share in three years, inside a segment that is itself growing at more than three times the rate of the category around it.

There are two ways to hit a dollar target and only one of them is in the company’s hands

A revenue target computed on a growing denominator is a share target in disguise, and the disguise is where the risk lives. If the segment grows at 10 percent a year instead of 15, USD 600 million reaches about USD 799 million by 2028 and the same USD 250 million is a share above 30 percent. If the segment grows at 20 percent, USD 600 million becomes about USD 1,037 million and the required share falls to about 24 percent. The company controls its own revenue line. It does not control the denominator, and the denominator is the part of the target that is never stated.

That asymmetry is the reason digital PCR forecasts diverge so widely across published work. Two analysts can agree entirely on how fast QIAcuity can grow and disagree by half on the size of the segment it is growing into, which is why the report states base year, segment weight and growth rate separately rather than as a single confident figure. The companion piece on addressable markets makes the same point from the other direction: a vendor’s view of a market is bounded by what the vendor sells.

Consolidation removed the alternative route

Bio-Rad closed its acquisition of Stilla Technologies on 7 July 2025. The competitive significance is not the consideration paid. It is that the second physical route into digital PCR — the nanoplate approach, which partitions a sample differently from the droplet systems that dominate the market — now sits inside a company that already sells the QX200 and the QX600.

Before that transaction, a laboratory buying a digital PCR platform was choosing between three independent technological positions. After it, the choice is between two large installed bases and one challenger. For QIAGEN that cuts both ways. Consolidation helps a challenger sell, because buyers prefer a platform with a service organisation and a reference list behind it, and the segment is small enough that a single large account moves the share. It also means the differentiation has to come from workflow and cost per reaction rather than from a distinct principle nobody else has.

This is the one place in the PCR category where a position can still be lost, which is why it belongs in a risk chapter rather than a growth chapter. The rest of the category is a share fight over a chemistry that has been settled for thirty years. Digital PCR is not settled.

What digital PCR is actually purchased to do

The distinction that matters commercially is that digital PCR does not replace quantitative PCR. It produces a measurement quantitative PCR cannot produce: absolute quantification without a standard curve, by partitioning a sample into thousands of reactions and counting positives rather than reading a cycle threshold. That matters for rare allele detection at fractions a standard curve cannot resolve, for copy number, and for any application where the answer has to be a concentration rather than a relative value.

That is why a segment this small can grow at roughly 15 percent inside a category growing at 4 to 5 percent. It is not taking share of routine testing. It is creating tests that previously had no method, and the buyer is often a laboratory that has already tried to answer the question on qPCR and found the answer too noisy to defend.

The constraint is the opposite of the one usually assumed. The physics works. The problem is cost per answer: partitioning a sample into thousands of reactions costs materially more in consumables than running one reaction, and every gain in the segment’s growth rate comes from closing that premium — through multiplexing, through reduced hands-on time, through smaller panels run at higher frequency. Digital PCR does not get cheaper because the science improves. It gets cheaper because the workflow does.

Six point three per cent of the base and one point of the growth rate

It is worth keeping the weight in view, because the enthusiasm around digital PCR consistently outruns its size. The segment is 6.33 percent of the 2025 PCR base of USD 10.42 billion. At 15 percent growth it contributes 0.95 of the 5.00 percentage points in the category forecast. Quantitative PCR contributes the other 4.06.

So the segment is simultaneously the most interesting part of the market and, for the next several years, a rounding item inside it. Both statements are true. The commercial question for a participant is not which is more exciting but which produces the margin: a qPCR reagent sold into a laboratory with an open protocol competes on price per unit, and a digital PCR consumable sold into a validated workflow competes on the answer it produces. The reagent economics piece follows that distinction through the instrument channel, where the box is a cost of acquiring the consumable rather than a product in its own right.

What would falsify the plan

Three observables would settle it within eighteen months, and none of them requires the company to say anything. Digital PCR instrument placements, which QIAGEN has already attributed to constrained academic capital spending in 2025, have to recover, because a consumable annuity begins with a box on a bench. Segment growth has to stay above roughly 8 percent, below which the share requirement climbs beyond what any single challenger has achieved in three years. And the installed base has to stay addressable, meaning no further consolidation that puts the remaining alternative platform behind a distribution agreement a laboratory cannot reach.

A forecast of 15 percent for a 6.33 percent segment is not a bet on the technology. It is a bet that the workflow gets cheap enough to sell outside the research laboratory, and that the market stays structurally open long enough for a challenger to reach 27 percent of it. Neither of those is guaranteed by the science, and a reader is entitled to hold both in view when they see the target quoted as though it were a result.